Lv2
188 积分 2025-06-04 加入
Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy
5天前
已完结
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer
9天前
已完结
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
16天前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
16天前
已完结
Balanced Permeability Index: A Multiparameter Index for Improved In Vitro Permeability
16天前
已完结
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space
16天前
已完结
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
16天前
已完结
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
17天前
已完结
New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders
17天前
已完结
Structural and Physicochemical Features of Oral PROTACs
17天前
已完结
皖公网安备34019202002308